Skip to main content
Premium Trial:

Request an Annual Quote

Hold on Tekmira, DoD Ebola Collaboration Extended for Additional Month

Premium

Tekmira Pharmaceuticals said last week that the US Department of Defense has extended the temporary stop-work order it recently imposed on its partnership with the company to develop an RNAi-based treatment for Ebola virus infection.

Tekmira said that it now expects to hear by Sept. 30 whether the order has been lifted or extended again, or whether the government is terminating the arrangement altogether.

Tekmira and the DoD had been working together on an Ebola drug for years. In 2010, Tekmira received a $34.7 million, three-year contract through the agency's Transformational Medical Technologies program to advance a therapeutic candidate called TKM-Ebola into phase I testing.

The DoD also has the option to extend the arrangement through to US Food and Drug Administration approval, which would result in approximately $140 million in funding to Tekmira.

However, Tekmira announced in August that the DoD had issued a temporary stop-work order on the Ebola contract citing budgetary constraints (GSN 8/9/2012).

At the time, Tekmira said it would get additional information on the fate of the Ebola alliance by Sept. 1.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.